Navigation Links
Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
Date:10/22/2007

Dr. Rene Bruno Will Present on the Value of Clinical Trial Simulations to

Predict Efficacy and Survival Benefit of Anticancer Agents

MOUNTAIN VIEW, Calif., Oct. 22 /PRNewswire-FirstCall/ -- Pharsight Corporation (OTC Bulletin Board: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Rene Bruno, Ph.D., managing director, Strategic Consulting Services, Europe, has been invited to speak to academics, regulators, and members of the Chinese pharmaceutical industry attending the International Symposium in Quantitative Pharmacology in Drug Development and Regulation. The symposium will be held in Nanjing China at the International Conference Hotel from October 29-31, 2007.

Dr. Bruno will join other leading experts from industry, government and academia in a scientific program that will discuss the latest methodologies in pharmacometrics, focusing on pharmacokinetic and pharmacodynamic (PK/PD) modeling and simulation in drug development, regulation and clinical applications. The symposium will also provide a forum for scientific discussion and collaborative exchange on model-based approaches in drug development. Dr. Bruno's presentation, discussing a model-based approach to support drug development in oncology, will be part of a session focusing on the theory and applications of model-based drug development. The presentation, entitled "Clinical Trial Simulations to Predict Efficacy and Survival Benefit of Anticancer Agents", will take place on October 29, 2007. Dr. Bruno also serves on the symposium's international advisory committee.

"Model-based drug development continues to grow as a value-added method for optimizing decisions in the drug development process," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "Drug development is benefiting from the quantitative application of drug-disease models to simulate expected clinical responses of new compounds, to support critical program strategies and enhance study design decisions. Pharsight is pleased to participate at this important international symposium, to discuss opportunities and challenges for global drug development and approval in the rapidly-growing Chinese pharmaceutical industry, and to exchange information with industry colleagues on the strategic use of modeling and simulation."

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trade marks of their respective companies or organizations.


'/>"/>
SOURCE Pharsight Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Why companies dont get invited to the DEMO conference
2. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
3. Wisconsin firms to present at Cleantech venture capital event
4. New Sonic Foundry search engine finds words, phrases in video presentations
5. Lone Wisconsin firm to present at InvestMidwest
6. Sonic Foundry creates search engine for 7,000 expert video presentations
7. InvestMidWest calls for business presentations
8. Wicab to present BrainPort at Boston conference
9. Three more Wisconsin firms to present at venture forum
10. Six Wisconsin firms to present at BIO Mid-America VentureForum
11. New Health and Human Services representative for Midwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... process optimization firm for the life sciences and healthcare industries, announces a presentation ... San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings announced ... by which its ProCell stem cell therapy prevents ... ischemia.  The Company, demonstrated that treatment with ProCell ... limbs saved as compared to standard bone marrow ... HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting in North ... in Harvard University’s Departments of Physics and Astronomy, has been selected for membership in ... winning team for the 2015 Breakthrough Prize in Fundamental physics for the discovery of ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System ... standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface electromyography ...
Breaking Biology Technology:
(Date:4/11/2017)... Apr. 11, 2017 Research and Markets has ... report to their offering. ... The global eye tracking market to grow at a CAGR of ... Eye Tracking Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):